Urology & Oncology & Family Medicine
Prostate-Specific Antigen (PSA)
Faire cette analyse
Prélèvements sanguins dans nos points de service au Québec. Un professionnel peut aussi interpréter vos résultats avec vous.
PSA - Prostate-Specific Antigen - is a glycoprotein of the kallikrein family (hKK3) synthesized exclusively by epithelial cells of the prostate gland, whether normal, hyperplastic or malignant. Its physiological function is to liquefy seminal coagulum after ejaculation, enabling spermatozoa to be mobilized. PSA is present in very high concentrations in seminal fluid (concentrations in the order of milligrams per milliliter), and a tiny fraction diffuses into the bloodstream, where it can be measured in trace amounts (nanograms per milliliter) in normal men. Elevation of serum PSA above age-adjusted reference values signals a disruption of prostatic glandular architecture - whether benign (benign prostatic hypertrophy, prostatitis, trauma) or malignant (prostatic adenocarcinoma) - allowing increased leakage of PSA into the circulation. Since its clinical introduction in the 1980s and widespread adoption in the 1990s, PSA has become the world's most prescribed tumor marker and the cornerstone of screening and monitoring for prostate cancer - the number one cancer in men in Canada, with around 24,600 new cases expected in 2023. However, PSA suffers from significant limitations that have fuelled a worldwide debate on the relevance of routine screening: its low specificity for cancer (60 to 75 % of biopsies performed for elevated PSA are negative for cancer), the risk of over-diagnosis of indolent cancers that would never have caused symptoms or death, and the resulting over-treatment with its side effects (incontinence, impotence). Contemporary screening strategies are moving towards a more individualized approach based on informed discussion between doctor and patient, the use of free/total PSA, PSA density, PSA velocity and new biomarkers (PHI - Prostate Health Index, 4Kscore, IsoPSA) to better select men for biopsy.
Age-adjusted reference values
| Age group | Total serum PSA (traditional threshold) | Clinical remarks |
|---|---|---|
| 40–49 years | < 2.5 µg/L (ng/mL) | Early screening recommended for men at high risk (African descent + family history of first-degree relative < 65 years) + baseline PSA at age 40 useful as a personal reference value |
| 50–59 years | Less than 3.5 µg/L | Recommended by the Canadian Cancer Society and the AUC: Age to start standard screening for average-risk men + informed patient-physician discussion. |
| 60-69 years old | Less than 4.5 µg/L | Prostate cancer prevalence increases with age, but so does BPH, which elevates PSA, making interpretation more delicate. The classic threshold of 4 µg/L is often used in this age group. |
| 70-79 years old | Less than 6.5 µg/L | The benefit of screening after 70 years of age decreases (reduced life expectancy + risk of overtreatment) + individualized screening according to general health and life expectancy + screening generally recommended to stop if life expectancy < 10 years |
| Note on the threshold of 4 µg/L | The classic threshold of 4 µg/L remains the most widely used universal threshold in practice, but it lacks sensitivity (15 % of significant cancers have a PSA < 4) and specificity (75 % of men with PSA between 4 and 10 µg/L do not have cancer upon biopsy). Age-adjusted thresholds and PSA refinement tools improve diagnostic performance. | |
Causes of elevated PSA
- Benign Prostatic Hyperplasia (BPH) most common cause of moderate chronic PSA elevation (4–10 µg/L) + prostate volume directly determines the amount of PSA secreted → approximately 0.3 µg/L per gram of benign prostate tissue + PSA density (PSA/prostate volume in cm³) < 0.15 µg/L/cm³ points towards a benign cause + a 70-year-old man with an 80 cm³ prostate can have a PSA that is «normal for his volume» at 24 µg/L (80 × 0.3)
- Acute bacterial prostatitis: The most frequent cause of acute and significant PSA elevation (sometimes > 50–100 µg/L) + intense inflammation → breakdown of tight junctions between epithelial cells → massive leakage of PSA into circulation + normalization after prostatitis healing in 4 to 8 weeks + never biopsy or interpret PSA in the context of acute prostatitis
- Prostate cancer: Cancer cells produce less PSA per cell than benign cells—but the disorganized glandular architecture of cancer (lack of intact basement membranes) allows for disproportionate leakage into circulation + high-grade cancers (Gleason 8–10) can have paradoxically low PSA because the highly dedifferentiated cells have lost the ability to synthesize PSA
- Prostatic manipulations: Digital Rectal Exam (DRE) → modest transient PSA elevation of 0.1 to 0.4 µg/L + reversible within 24–48 h + cystoscopy → greater elevation + prostate biopsy → major elevation (PSA can reach 20–40 µg/L) which normalizes in 4 to 6 weeks + ejaculation → elevation of 0.5 to 1 µg/L over 24–48 h → ideally no ejaculation within 48 h prior to testing + intense physical effort (cycling) → modest elevation
- Medications that lower PSA 5-alpha-reductase inhibitors (finasteride Proscar® + dutasteride Avodart®) → reduce PSA by 40-50% % after 6 months → for patients on these medications, the measured value must be doubled to estimate the «corrected» PSA + anti-androgens + LHRH + castration → reduce PSA to almost zero (treatment response monitoring tool)
Diagnostic Refinement Tools Beyond Total PSA
| Tool | Definition and calculation | Interpretation and clinical utility |
|---|---|---|
| Free PSA / Total PSA Ratio (% Free PSA) | Dans le sang, le PSA circule sous deux formes : PSA libre (non lié — 10–30 %) + PSA complexé à des protéines (ACT + A2M — 70–90 %) + dans le cancer : proportion de PSA libre plus basse que dans l'HBP (le cancer produit plus de PSA complexé) → ratio PSA libre/total 25 % → risque faible → surveillance possible | Useful in the PSA gray zone of 4–10 µg/L to reduce unnecessary biopsies + sensitivity 95% + specificity 18–36% depending on the threshold + to be avoided if PSA > 10 µg/L (always biopsy) or < 4 µg/L (less relevant) + strict collection conditions (rapid centrifugation + freezing) |
| PSA density | PSA total (µg/L) ÷ prostate volume (cm³ on transrectal ultrasound or MRI) + normalizes PSA by gland volume → corrects for prostate size | PSA density 0.15 µg/L/cm³ → higher risk of clinically significant cancer → biopsy recommended even if total PSA is borderline |
| PSA Velocity | Annual PSA variation = (Current PSA - Previous PSA) ÷ interval in years + measures PSA velocity over time + requires at least 2 measurements spaced 12 to 18 months apart in the same laboratory | PSAV > 0.75 µg/L/year (if PSA > 4) → increased risk of cancer + PSAV > 0.35–0.4 µg/L/year (if PSA is between 2 and 4) → warning sign + a rapid rise in PSA is often more informative than the isolated absolute value |
| Multiparametric prostate MRI (mpMRI) | 3 Tesla MRI with T2 sequences + diffusion (ADC) + dynamic perfusion + PI-RADS v2.1 classification (1 = very unlikely + 5 = very likely) + performed before biopsy or to guide targeted biopsies | PI-RADS 1–2 → possible deferred biopsy + PI-RADS 3 → individualized decision + PI-RADS 4–5 → MRI-TRUS fusion biopsy recommended + improves detection of clinically significant cancers + reduces detection of insignificant cancers + recommended before any initial biopsy (EAU guidelines 2023) |
| Prostate Health Index (PHI) | Formula combining total PSA + free PSA + [-2]proPSA (truncated form of PSA precursor) → PHI = ([-2]proPSA ÷ free PSA) × √total PSA + normal values: PHI 36 (high risk) | Superior to total PSA and the free/total PSA ratio in predicting clinically significant cancer (Gleason ≥ 7) + allows for a 30-40% reduction in unnecessary biopsies % + available in select Canadian laboratories |
ℹ️
The decision to biopsy or not after a high PSA should never rest solely on total PSA; it must integrate age, life expectancy, family history, digital rectal exam, free-to-total PSA ratio, PSA density, velocity, and ideally multiparametric MRI of the prostate. A PSA between 4 and 10 µg/L in the gray zone is a signal that warrants investigation, but not necessarily immediate biopsy. Informed physician-patient discussion about the benefits and risks of screening is at the heart of current recommendations from the Canadian Cancer Society and the Canadian Urological Association (CUA).
Prostate Cancer Screening — Canadian Recommendations
- Men at medium risk: Informed discussion for men over 50 on the benefits and risks of PSA screening. If screening is decided upon: annual PSA + rectal exam, or every 2 years depending on results. Discontinue screening if life expectancy is limited. Under 10 years old or poor general condition
- High-risk men: Screening begins at 40-45 years old + Black or Caribbean men (1.5 to 2 times higher risk) + family history of prostate cancer in a first-degree relative diagnosed before age 65 + BRCA2 mutation (very high risk of aggressive cancer)
- Follow-up after curative treatment (surgery or radiotherapy): after radical prostatectomy → undetectable PSA< 0,1 µg/L) attendu + récidive biochimique si PSA ≥ 0,2 µg/L sur deux dosages consécutifs + après radiothérapie → nadir PSA (valeur minimale atteinte) + récidive biochimique si PSA > nadir + 2 µg/L (Phoenix criterion)
- Active Surveillance low-risk cancers (PSA (Gleason score < 7 + stage T1c-T2a + minimal biopsy involvement) → surveillance without immediate treatment + PSA every 3–6 months + repeat biopsies at 1 year, then every 2–3 years + annual MRI + treatment initiated if progression → avoids overtreatment of indolent cancers while allowing early detection of progression to aggressive cancer
Medical consultation recommended
Consult a doctor or urologist quickly if a PSA is above 10 µg/L regardless of age group, or above age-adjusted thresholds with rapid progression (high velocity), or if a rectal exam reveals a hard nodule or suspicious asymmetry. These findings necessitate a urological evaluation with multiparametric MRI and discussion of biopsy without undue delay. A very significant acute elevation of PSA in the context of fever, dysuria, and perineal pain requires first ruling out acute bacterial prostatitis to be treated before any biopsy.
For PSA testing, its interpretation in a clinical context, the discussion on prostate cancer screening, and urological referral, Clinique Omicron offers medical consultations at its service points in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
Consult at Clinique Omicron
Clinique Omicron's nurse practitioners (NPs) prescribe and interpret total PSA as part of prostate cancer screening after an informed discussion with the patient, order the free/total PSA ratio and PSA density as appropriate, perform the digital rectal exam, refer to urology for multiparametric MRI and biopsy if indicated, and manage PSA follow-up after curative treatment. Consultations are available at several service points in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not replace the advice of a doctor or urologist. Prostate cancer screening with PSA is an individualized medical decision involving an informed discussion of benefits (reduced specific mortality), risks (over-diagnosis + over-treatment), and surveillance alternatives.
Omicron Clinic
Need to consult a doctor?
En clinique ou en télémédecine, partout au Québec.
Reçus pour assurances. Téléconsultation 7 j/7. Sans médecin de famille requis.